DXC Technology cleared the bar on paper. Fiscal second-quarter non-GAAP EPS of $0.67 topped the $0.55 consensus by 9.8% and beat the $0.61 Earnings Whisper number. Revenue of $3.034 billion was 1.5% above the $2.99 billion estimate. Underneath the beat, earnings still fell 20.2% year over year and revenue declined 4.0%. Management also used the call to cut full-year guidance on revenue, margin, EPS and free cash flow. That is the central tension: a headline beat that was largely manufactured by a single contract event, attached to a forward outlook that got meaningfully worse.

The quality of the beat deserves scrutiny. Insurance revenue jumped 23.1% organically and segment profit rose 60.7%, but the release notes that growth included a favorable contract modification signed during the quarter. The call acknowledged that, excluding this item, results were only roughly in line. The core businesses deteriorated:

• **GIS:** revenue fell 10.0%, segment profit dropped 45.9%, and margin compressed to 4.6% from 7.7%.
• **CES:** revenue slipped 3.3%, and margin fell to 10.3% from 11.6%.
• **Consolidated:** adjusted EBIT declined 26.4% to $187 million, and margin contracted 180 basis points to 6.2%.

On a GAAP basis the picture is thinner still. EBIT fell 52.2% to $66 million, and diluted EPS was just $0.15, down from $0.20. Per-share results also had help from a roughly 10% lower diluted share count. Quarterly free cash flow fell to $91 million from $240 million, although first-half free cash flow of $405 million ran ahead of last year's $337 million.

The more damaging disclosure was bookings. Q2 bookings fell 10% to $2.4 billion, and book-to-bill dropped to 0.80x. That compares with 0.99 in Q1 and 1.07 in Q4 FY26. CES bookings fell 17% and GIS bookings 13%. Management cited lower win rates and stiffer competition in the Americas, slipped UK and Ireland public-sector deals, and clients shortening contract terms from five years to two. Customers are also adding agentic-versus-traditional evaluations to decision cycles. Management said it is "not satisfied" and called some losses "self-made." That is a sharp change from Q1, when management described more opportunity than risk in the guide and touted six-week AI sales cycles. The company now assumes weak pipeline conversion persists through the second half.

The guidance cuts reflect that shift:

• **Organic revenue:** now a 5.0%–5.5% decline, versus the 3%–5% decline reaffirmed in each of the prior two quarters.
• **Segments:** CES moved to a mid-single-digit decline, reversing Q1's upgrade, and GIS moved to a high-single-digit decline.
• **Adjusted EBIT margin:** narrowed to 5.75%–6.25% from 6%–7%.
• **Non-GAAP EPS:** reset to $2.25–$2.50 from $2.40–$2.90.
• **Free cash flow:** about $600 million versus roughly $685 million previously.
• **Q3:** about $0.55 in EPS on a roughly 6% organic revenue decline, implying further year-over-year erosion.

Management is responding with an expanded cost-takeout plan and is evaluating deeper FY28 actions.

The bull case rests on catalysts rather than the core trajectory. DXC confirmed ongoing discussions about a possible sale of its insurance business. On the call, the Guidewire/hyperexponential deal at roughly 20 times revenue was cited as a valuation reference. On AI, the company pointed to several early wins:

• its first large GrowthX modernization-as-a-service win with a global bank, built on Anthropic's Claude, with seven to eight follow-on projects referenced;
• OASIS utilization up sixfold sequentially;
• the launch of Frontier Code Assurance and a LangChain partnership;
• more than 5,700 AI-certified employees.

These are credible early signals, but they remain small against a $12 billion revenue base shrinking mid-single digits.

The market setup is more complicated than the surprise implies. Shares closed at $16.09 the day before the report, up 43.8% from the open after the July release and 39% above the 200-day moving average of $11.58. The stock entered earnings just 1.8% below a 52-week high of $16.38 set on October 26. The run was compressed into a short window: the inter-earnings low of $10.13 came only on September 29. Investor sentiment remained negative but improved meaningfully, from -0.36 to -0.11. Price and AVWAP trend readings are positive while sequential growth is negative, which matches a stock rallying on event potential while the operating trend worsens. Much of that rerating appears tied to the insurance-sale story rather than to the core business that just lowered its outlook.

The bottom line is that DXC's beat was flattered by a one-time insurance gain and did little to offset a weak bookings quarter, three consecutive guidance-direction reversals capped by a broad cut, and a more chastened management tone. Bears have legitimate ammunition in the 0.80x book-to-bill and the GIS margin collapse. Bulls are leaning on a potential insurance divestiture and nascent AI traction. With the stock near its high and well above trend, the outcome of the insurance-sale talks now matters more to the near-term setup than the quarter's headline beat.